glp 1 agonist risks Managing Side Effects of GLP-1 Receptor Agonists – Transformation Weight Control The expanding role of GLP-1

Thirdly , theres also a patent application (IN202047010224) (pdf) pending by Novo Nordisk, filed in 2020 with priority date of 24/08/2017, for a specific formulation of semaglutide (the active ingredient in its commercial blockbuster drug, Ozempic) described as Semaglutide liquid formulations (no more than 0.01% (w/w) phenol. Adding to the complexity is a recent revocation petition filed by DRL in May 2025 (as reported by the media here)

Like LIR, the race of patients involved in related clinical studies is relatively small

Its core features include structural abnormalities of the myocardiumsuch as ventricular hypertrophy, dilation, or fibrosisand functional impairments involving either systolic or diastolic dysfunction [36]

A narrative review of 10 primary studies that assessed energy intakes in GLP-1 RA users revealed that total calorie intake was reduced by 16 to 39% in a single meal 25

As the potential uses of these drugs expand, such as with recent approvals to prevent heart attacks and strokes in adults with cardiovascular disease who are overweight, the high cost and increased demand for these drugs may increase health spending